Karo Pharma AB (Karo Pharma AB) Common Stock : $10.9 Mil (As of Jun. 2022)

View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Common Stock?

Karo Pharma AB's quarterly common stock declined from Sep. 2021 ($10.4 Mil) to Dec. 2021 ($9.9 Mil) but then increased from Dec. 2021 ($9.9 Mil) to Jun. 2022 ($10.9 Mil).

Karo Pharma AB's annual common stock increased from Dec. 2019 ($9.5 Mil) to Dec. 2020 ($10.8 Mil) but then declined from Dec. 2020 ($10.8 Mil) to Dec. 2021 ($9.9 Mil).

Karo Pharma AB Common Stock Historical Data

The historical data trend for Karo Pharma AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Common Stock Chart

Karo Pharma AB Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Common Stock

Get a 7-Day Free Trial

4.93

7.28

9.54

10.76

9.90

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
Common Stock	Get a 7-Day Free Trial															10.54	10.72	10.41	9.90	10.89

Karo Pharma AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Karo Pharma AB (Karo Pharma AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22

Website

https://www.karopharma.com

Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire • 06-25-2019